These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 17952738)
1. Tyrosine kinase inhibitors in pediatric malignancies. Skolnik JM; Adamson PC Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738 [TBL] [Abstract][Full Text] [Related]
2. Role of tyrosine kinase inhibitors in cancer therapy. Arora A; Scholar EM J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463 [TBL] [Abstract][Full Text] [Related]
3. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Steeghs N; Nortier JW; Gelderblom H Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252 [TBL] [Abstract][Full Text] [Related]
4. Inhibitors of signal transduction protein kinases as targets for cancer therapy. Mikalsen T; Gerits N; Moens U Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195 [TBL] [Abstract][Full Text] [Related]
5. [Protein tyrosine kinase inhibitors in cancer therapy]. Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095 [TBL] [Abstract][Full Text] [Related]
6. [Imatinib--a new perspective in the treatment of tumors]. Klener P; Klamová H Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894 [TBL] [Abstract][Full Text] [Related]
7. The biology of signal transduction inhibition: basic science to novel therapies. Griffin J Semin Oncol; 2001 Oct; 28(5 Suppl 17):3-8. PubMed ID: 11740801 [TBL] [Abstract][Full Text] [Related]
8. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Faivre S; Djelloul S; Raymond E Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796 [TBL] [Abstract][Full Text] [Related]
9. New tyrosine kinase inhibitors in chronic myeloid leukemia. Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950 [TBL] [Abstract][Full Text] [Related]
10. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. Chase A; Cross NC Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463 [TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Kantarjian HM; Talpaz M Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802 [TBL] [Abstract][Full Text] [Related]
13. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer. Zámečníkova A Expert Opin Drug Discov; 2014 Jan; 9(1):77-92. PubMed ID: 24294890 [TBL] [Abstract][Full Text] [Related]
14. Resistance to tyrosine kinase inhibitors: calling on extra forces. Cools J; Maertens C; Marynen P Drug Resist Updat; 2005 Jun; 8(3):119-29. PubMed ID: 15869901 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Engelman JA; Settleman J Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754 [TBL] [Abstract][Full Text] [Related]